Targeted therapies against type I interferon and TNF-alpha in cutaneouslupus erythematosus: A systematic review of randomized trials
Dermatology Online Journal · 06.07.2026 · 32 (3)
DOI: 10.25251/mgn4rt3l ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatology Online Journal, online erschienen am 06.07.2026. Verfasst von Daniela Andrea Candia González und 5 weiteren Autor:innen. Beteiligte Einrichtung: Universidad del Norte, Barranquilla, Colombia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Interferon Type I, Tumor Necrosis Factor-alpha, Molecular Targeted Therapy. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cutaneous lupus erythematosus (CLE) is associated with high symptomatic burden and sustained activation of immune pathways, notably type I interferon (IFN-I) and tumor necrosis factor-alpha (TNF-α). In patients refractory to standard treatments, such as photoprotection, corticosteroids, antimalarials, and immunomodulators, targeted therapies have emerged as potential alternatives.
Objective
To assess the efficacy and safety of targeted therapies against IFN-I or TNF-α compared to standard treatments in patients with CLE.
Methods
A systematic review was conducted of randomized controlled trials (RCTs) involving adults or adolescents with CLE (with or without systemic lupus erythematosus), reporting cutaneous outcomes (CLASI-A, CLASI-50, responder rates) and safety. Literature searches were performed in MEDLINE, Embase, and LILACS without language restrictions. Risk of bias was evaluated using the Cochrane RoB 2 tool. Owing to clinical heterogeneity, results were synthesized narratively.
Results
Eight RCTs met inclusion criteria, predominantly evaluating IFN-I pathway inhibitors. Anifrolumab showed significant benefit in TULIP-2 (CLASI-50: 49% vs 25%; P = .001) and MUSE (63% vs 30.8%). Sifalimumab achieved CLASI-50 responses up to 73%. Deucravacitinib (TYK2 inhibitor) and BIIB059 (anti-BDCA2) also showed clinical improvements. RSLV-132 and epratuzumab did not demonstrate efficacy. IFN-I blockade was associated with increased viral infections, particularly herpes zoster. Two studies were rated as high risk of bias; the remainder presented some concerns.
Conclusion
Targeted inhibition of IFN-I and TYK2 pathways appears effective in reducing cutaneous activity in CLE, with acceptable safety profiles. Evidence for anti-TNF therapies remains insufficient. Further trials stratified by CLE subtype and patient-reported outcomes are warranted to inform clinical guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universidad del Norte, Barranquilla, Colombia.
- Universidad de Los Andes, Bogotá, Colombia.
- Universidad del Rosario, Bogotá, Colombia.
- Universidad Nacional de Colombia, Bogotá, Colombia.
- Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia.
Zitieren
APA
Candia González, D. A., Dávila Vargas, D., Arango Machado, V., Araque Díaz, V., Alzate Granado, J. P., & Gómez Ballesta, F. J. (2026). Targeted therapies against type I interferon and TNF-alpha in cutaneouslupus erythematosus: A systematic review of randomized trials. Dermatology Online Journal, 32(3). https://doi.org/10.25251/mgn4rt3l
Vancouver
Candia González DA, Dávila Vargas D, Arango Machado V, Araque Díaz V, Alzate Granado JP, Gómez Ballesta FJ. Targeted therapies against type I interferon and TNF-alpha in cutaneouslupus erythematosus: A systematic review of randomized trials. Dermatology Online Journal. 2026;32(3). doi:10.25251/mgn4rt3l
BibTeX
@article{CandiaGonzlez2026,
author = {Candia González, Daniela Andrea and Dávila Vargas, Daniela and Arango Machado, Verónica and Araque Díaz, Valentina and Alzate Granado, Juan Pablo and Gómez Ballesta, Francisco Javier},
title = {Targeted therapies against type I interferon and TNF-alpha in cutaneouslupus erythematosus: A systematic review of randomized trials},
journal = {Dermatology Online Journal},
year = {2026},
volume = {32},
number = {3},
doi = {10.25251/mgn4rt3l}
}
EUVIMED